Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11

被引:26
作者
Cao, Q
Abeysinghe, H
Chow, O
Xu, J
Kaung, HL
Fong, CT
Keng, P
Insel, RA
Lee, WCM
Barrett, JC
Wang, N [1 ]
机构
[1] Dept Pathol & Lab Med, Rochester, NY USA
[2] Dept Pediat, Rochester, NY USA
[3] Univ Rochester, Sch Med & Dent, Dept Radiat Oncol, Rochester, NY USA
[4] Case Western Reserve Univ, Dept Anat, Cleveland, OH 44106 USA
[5] NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1016/S0165-4608(01)00442-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the pathogenic role of chromosomes 11 and 17 in the carcinogenesis of human ovarian cancers, neo(R)-tagged chromosome 11 or 17 was transferred from cell lines A9H11 or A9H17 respectively, into the ovarian carcinoma cell line SKOV-3 using microcell-mediated chromosome transfer. The chromosome transfer was verified by polymerase chain reaction detection of the neo(R) gene, fluorescence in situ hybridization detection of an extra chromosome 11, and microsatellite polymorphism detection of an exogeneous chromosome It. Five SKOV-3/A9H11 hybrids and five SKOV-3/A9H17 hybrid clones were generated. For the chromosome 11 transfer. complete suppression of tumorigenicity was observed in four clones. (11)9-8 and 11(H)7-2. 11(H)8-3 and 11(H)7-2. 100 days post implantation. For the chromosome 17 transfer, no complete suppression of tumorigenicity was observed. However. an increased latency period ranging from 25 to 49 days in contrast to 7 days for the SKOV-3 parental line, and a significant reduction in tumor size was observed. There was no correlation between the in vitro growth rate and the tumorigenicity or length of latency period. Our results demonstrate functionally that chromosome 11 may carry a tumor suppressor gene(s) while chromosome 17 may carry a tumor growth-inhibitor gene(s) for the ovarian carcinoma cell line. SKOV-3. (C) 2001 Elsevier Science Inc. All rig-hts reserved.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 28 条
  • [1] BAUMAL R, 1986, CANCER RES, V46, P3994
  • [2] BUICK RN, 1985, CANCER RES, V45, P3668
  • [3] CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO
  • [4] 2-Y
  • [5] FUNCTIONAL EVIDENCE FOR A BREAST-CANCER GROWTH SUPPRESSOR GENE ON CHROMOSOME-17
    CASEY, G
    PLUMMER, S
    HOELTGE, G
    SCANLON, D
    FASCHING, C
    STANBRIDGE, EJ
    [J]. HUMAN MOLECULAR GENETICS, 1993, 2 (11) : 1921 - 1927
  • [6] CLIBY W, 1993, CANCER RES, V53, P2393
  • [7] ECCLES DM, 1992, DIS MARKERS, V10, P95
  • [8] EHLEN T, 1990, ONCOGENE, V5, P219
  • [9] VERY FREQUENT LOSS OF HETEROZYGOSITY THROUGHOUT CHROMOSOME-17 IN SPORADIC OVARIAN-CARCINOMA
    FOULKES, WD
    BLACK, DM
    STAMP, GWH
    SOLOMON, E
    TROWSDALE, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1993, 54 (02) : 220 - 225
  • [10] LOSS OF HETEROZYGOSITY AND AMPLIFICATION ON CHROMOSOME-11Q IN HUMAN OVARIAN-CANCER
    FOULKES, WD
    CAMPBELL, IG
    STAMP, GWH
    TROWSDALE, J
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (02) : 268 - 273